Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Frovatriptan: a review.

Jerome Goldstein1

  • 1San Francisco Headache Clinic, 909 Hyde Street, Suite 322, San Francisco, CA 94109, USA. SFHACLIN@aol.com

Expert Opinion on Pharmacotherapy
|January 9, 2003
PubMed
Summary
This summary is machine-generated.

Frovatriptan, a potent migraine medication, offers high efficacy and low recurrence rates. Its favorable safety profile and long half-life make it a valuable treatment option for many migraine sufferers.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sumatriptan iontophoretic transdermal system: A novel approach to migraine-specific therapy.

Neurology. Clinical practice·2018
Same author

Spontaneous coronary artery dissection.

Singapore medical journal·2017
Same author

Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: long-term results from a randomized, multicenter, double-blinded, controlled study.

Cephalalgia : an international journal of headache·2014
Same author

Results of a multicenter, double-blind, randomized, parallel-group, placebo-controlled, single-dose study comparing the fixed combination of acetaminophen, acetylsalicylic acid, and caffeine with ibuprofen for acute treatment of patients with severe migraine.

Cephalalgia : an international journal of headache·2014
Same author

The efficacy of transdermal sumatriptan is too low for general use - a response.

Headache·2014
Same author

Sumatriptan/naproxen sodium for the acute treatment of probable migraine without aura: a randomized study.

Cephalalgia : an international journal of headache·2013
Same journal

Pharmacotherapeutic interventions for pediatric ulcerative colitis.

Expert opinion on pharmacotherapy·2026
Same journal

The rise and fall of TRPV1-targeted analgesia in osteoarthritis: a critical appraisal.

Expert opinion on pharmacotherapy·2026
Same journal

Dopamine transporter and beyond: evolving targets and combination strategies in stimulant use disorder.

Expert opinion on pharmacotherapy·2026
Same journal

GnRH antagonists for the treatment of fibroids and adenomyosis, current evidence and future perspectives.

Expert opinion on pharmacotherapy·2026
Same journal

Pharmacotherapeutic strategies for the management of congenital adrenal hyperplasia.

Expert opinion on pharmacotherapy·2026
Same journal

Current advances in pharmacotherapeutic strategies for the treatment of complicated intra-abdominal infections.

Expert opinion on pharmacotherapy·2026
See all related articles

Area of Science:

  • Pharmacology
  • Neurology
  • Clinical Therapeutics

Background:

  • Frovatriptan is a selective 5-HT(1B/1D) receptor agonist.
  • It exhibits the highest 5-HT(1B) receptor potency within the triptan class.
  • Preclinical studies suggest cerebro-selectivity.

Purpose of the Study:

  • To evaluate the clinical pharmacology, efficacy, and safety of frovatriptan.
  • To assess its pharmacokinetic profile, including half-life and drug interaction potential.
  • To determine its suitability for acute migraine treatment.

Main Methods:

  • Clinical pharmacology studies assessed tolerability and pharmacokinetics.
  • Efficacy was evaluated through response rates compared to placebo.
  • Safety was assessed by comparing side effect profiles.

Related Experiment Videos

Main Results:

  • Frovatriptan demonstrated a long elimination half-life (26 hours) and good tolerability across a wide dosage range (1-100 mg).
  • It showed a low potential for drug interactions due to minimal cytochrome P450 effects and low protein binding.
  • Efficacy studies revealed significantly higher response rates than placebo and the lowest headache recurrence rates in the triptan class; safety profile was similar to placebo.

Conclusions:

  • Frovatriptan's cerebro-selectivity, long half-life, efficacy, low recurrence rates, and tolerability position it as a valuable option for acute migraine treatment.
  • It is particularly suitable for patients with long-duration migraines, those prone to recurrence, or those experiencing triptan-related side effects.
  • No dosage adjustments are needed for age, renal, or hepatic impairment.